Every number, name, date and link in the text above comes from this list; software checks that before the text is stored. This text was assembled directly from the facts, without a language model.
Insiders
- In the 12 months to Nov 19, 2026, insiders of Bridgebio Oncology Therapeutics filed 0 open-market purchases (about $0, in 0 filings, by 0 people) and 1 open-market sale (about $185, in 1 filing, by 1 person). One Form 4 can list many transactions.
- In the 12 months before that, they filed 0 open-market purchases (about $0, in 0 filings) and 0 open-market sales (about $0, in 0 filings).
- The largest sale: Marc Cobo, Principal Accounting Officer, about $185, filed Nov 17, 2026.
Funds and stakes
- Fund 13F filings recorded in the 12 months show 1 new or larger position and 1 smaller or closed position. A 13F is a snapshot of holdings at the end of a quarter.
- Deerfield Management Company, L.P. cut its BBOT stake below 5% (3.9%) (filed Nov 13, 2026).
Contracts, lobbying and filings
- FINRA short interest for BBOT on the settlement date of Oct 30, 2026 was 3,468,496 shares (-9.82% on the previous report), about 5.1 days of average volume.
- In 13F filings for the quarter ended Jun 30, 2026, the largest positions that grew: none on record; the largest that shrank: Eventide Asset Management, LLC (sold out); Bellevue Group AG (sold out). A 13F is a quarter-end snapshot with no trade date.
Company reports, price and press
- Bridgebio Oncology Therapeutics filed a Form 8-K on Nov 5, 2026 (Item 5.02) that OQRO classes as: changed a top executive or board member.
- The company's own opening sentence of that report reads: "On October 30, 2026, Yong Ben, M.D., M.B.A. provided notice of his resignation as the Chief Medical and Development Officer of BridgeBio Oncology Therapeutics, Inc. (the 'Company'), effective January 8, 2027."
- Bridgebio Oncology Therapeutics filed a Form 8-K on Jun 22, 2026 (Items 5.02, 5.07) that OQRO classes as: changed a top executive or board member, and held a shareholder vote.
- The company's own opening sentence of that report reads: "On June 16, 2026, Michelle Doig notified BridgeBio Oncology Therapeutics, Inc. (the 'Company'), of her resignation as a member of the Board of Directors of the Company (the 'Board') upon the completion of her term as a Class I di..."
- Bridgebio Oncology Therapeutics filed a Form 8-K on Apr 29, 2026 (Item 5.02) that OQRO classes as: changed a top executive or board member.
- The company's own opening sentence of that report reads: "Departure of Director or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers."
- Press coverage listed by Finnhub: "BBOT Reports Third Quarter 2026 Financial Results and Update on Corporate Progress" (Yahoo, Nov 10, 2026).
- Press coverage listed by Finnhub: "BBOT to Participate in Upcoming Investor Healthcare Conferences" (Yahoo, Sep 1, 2026).
- Press coverage listed by Finnhub: "BBOT Reports Second Quarter 2026 Financial Results and Update on Corporate Progress" (Yahoo, Aug 11, 2026).
- BBOT closed at $1.81 on Nov 18, 2026, the last session on or before the end of the period.
- From Oct 19, 2026 to Nov 18, 2026, the close moved from $2.85 to $1.81, a change of −36.7%.
Who holds it
- 66 funds reported a stake in Bridgebio Oncology Therapeutics in their 13F for Q2 2026. The largest by value: Cormorant Asset Management, LP (30.2% of the value reported), DEERFIELD MANAGEMENT COMPANY, L.P. (8.3% of the value reported), Omega Fund Management, LLC (5.6% of the value reported).
Things to keep in mind
- These are counts of the filings OQRO holds, in the days they were filed; a busy or quiet month does not say why.
- A Form 4 reports a transaction; it does not say why it was made, and some follow trading windows or pre-arranged plans. Congress reports give only amount ranges and arrive after the trade.
- An 8-K item says what the company reported, not what it means for the share price.
- Headlines are listed as published by the outlets; OQRO has not checked them and does not summarise articles.
- Share price moves are listed as context only; the filing does not explain them and other news can move a price.
- This describes public filings. It is not investment advice.
Records
- Bridgebio Oncology Therapeutics on OQRO
- Largest sale, Nov 17, 2026
- Ownership filing, Nov 13, 2026
- Form 8-K of Nov 5, 2026
- Form 8-K of Jun 22, 2026
- Form 8-K of Apr 29, 2026
- Yahoo, Nov 10, 2026
- Yahoo, Sep 1, 2026
- Yahoo, Aug 11, 2026
- Who owns Bridgebio Oncology Therapeutics